Methods for treating or preventing asthma by administering an il-4r antagonist

A method for reducing the incidence of one or more asthma exacerbations or improving one or more asthma-associated parameters in a subject suffering from eosinophilic asthma comprising administering to the subject a pharmaceutical composition comprising an antibody or an antigen-binding fragment thereof that specifically binds to interleukin-4 receptor (IL-4R), wherein the antibody or antigen-binding fragment comprises three heavy chain complementarity determining region (HCDR) sequences comprising SEQ ID NOs:

• 148, 150, 152, respectively, and three light chain complementarity determining region (LCDR) sequences comprising SEQ ID NOs:
• 156, 158 and 160, respectively.

A method for the treatment of eosinophilic asthma in a subject whose asthma is inadequately controlled with moderate-to-high dose inhaled corticosteroid (ICS) and a second controller medication, comprising sequentially administering to the subject a single initial dose of a pharmaceutical composition comprising an antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof specifically binds an interleukin-4 receptor (IL-4R), and wherein administration of the single initial dose is followed by one or more secondary doses of the pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises heavy chain and light chain complementarity determining region (CDR) sequences from a heavy chain variable region (HCVR)/light chain variable region (LCVR) sequence pair of SEQ ID NOs:

• 162/164, wherein the pharmaceutical composition is an add-on treatment.